#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

INTRAVESICAL INSTILLATION THERAPY IN THE TREATMENT OF SUPERFICIAL BLADDER CARCINOMA


Authors: K. Karmašová;  V. Vít;  D. Pacík
Authors‘ workplace: Urologická klinika, FN Brno
Published in: Urol List 2011; 9(3): 22-26

Overview

Bladder tumours represent a challeging topic regarding both the adequate and early diagnostics and choice of suitable therapy. The author presents an overview of intravesical therapy options including the recommended schedules and comparison of individual modalities.

Key words:
transitional cell tumors, intravesical chemoterapy, intravesical immunotherapy


Sources

1. UZIS 2011; www.svod.cz

2. Ro JY, Staerkel GA, Ayala AG. Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am 1992; 19(3): 435–453.

3. Lopez-Beltran A, Cheng L, Anderson L et al. Pre­neo­plastic non-papilary conditions of the urinary bladder. Virchow Arch 2002; 440(1): 3–11.

4. Epstein J, Amin M, Reuter V et al. The Word Health Organisation/International Society of Urological pathology konsensus classification of urothelial neoplasms of the urinary bladder. Am Surg Pathol 1998; 22(12): 1435–1448.

5. Young R, Eble J. Unusual forms of carcinoma of urinary bladder. Hum Pathol 1991; 22(10): 948–965.

6. Dušková J. Patologie reaktivních změn, dysplazií a nádorů močového měchýře. Onkourologie. Praha: Karolinum 2005.

7. Holmang S, Hedelin H, Anderström C et al. The importance of depth of invasion in stage T1 of bladder carcinoma. A prospective study. J Urol 1197; 157(3): 800–804.

8. Cheng L, Cheville J, Neumann R et al. Survival of patiens with carcinoma in situ of urinary bladder. Cancer 1999; 85(11): 2469–2474.

9. Oesterlinck W, Lobel B, Jakse G et al. Guidelines on bladder cancer. Eur Urol 2002; 41(2): 105–112.

10. Czerniak B, Chatuverdi V, Li L et al. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia. Implications for a genetic model fo multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 1999; 18(5): 1185–1196.

11. Tomson C, Porter T. Asymptomatic microscopic or dipstic haematuria in adults. Which investigation for which patients? A review of evidence. Br J Urol Int 2002; 90(3): 185–198.

12. Soloway M, Sofer M, Vaidya A et al. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002; 167(4): 1573–1583.

13. Millan- Rodriguez F, Chechile-Toniolo G, Slavador-Bayarri J et al. Primary superficial bladder cancer risk Gross accroding to progression, mortality et recu­rence. J Urol 2000; 164 (3 Pt 1): 680–684.

14. Trasher JB, Crawford E. Compliacations of intra­vesical chemotherapy. Urol Clin North Am 1992; 19(3): 529–539.

15. Ali-El-Dein B, El-Baz M, Aly A et al. Intravesical epirubicin versus doxorubicin for superficial bladder tumors(stages pTa and pT1) A randomized prospective study. J Urol 1997; 158(1): 68–74.

16. Boehle A, Jocham D, Bock P. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer. A formal meta-analysis of komparative studies on recurrence nad toxicity. J Urol 2003; 169(1): 90–96.

17. Witjes JA, van der Heijden AG, Vriesem JL et al. Intravesical gemcitabin: a phase 1 and pharmacokinetic study. Eur Urol 2004; 45(2): 182–186.

18. Oesterlinck W, Kurth KH, Schroder F et al. A prospective European Organisation for Research and Treatment of Cancer genitourinary group randomized trail comparing transurethral followed by a single intravesical instilation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993; 149(4): 749–752.

19. Babjuk M, Oesterlinck W, Sylvester R et al. EAU Gulidelines on Ta T1 (Non-muscle invasive) Bladder cancer 2008: 1–22.

20. Kliment J. Intravezikálna imunoterapia. In: Ondruš D et al. Nádory močového mechúra diagnostika a liečba. Martin: Osveta 2000. 215–231.

21. Morales A, Chin J, Ramsey E. Mycobacterial cell wal extract for treatment of carcinoma in situ of the bladder. J Urol 2001; 166(5): 1633–1638.

22. Belldegruin A, Franklin J, Donnel E et al. Super­ficial bladder cancer: the role of interferon alfa. J Urol 1998; 159(6): 1793–1801.

23. Morales A, Edinger D, Bruce A. Intracavi-tary bacilus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116(2): 180–182.

24. Bohle A, Jocham D. Intravesical Imunotherapy with Bacillus Calmette-Guerin facts, figures, and re­sults. 2000. Urban & Fischer Verlag, Munchen, Jena.

25. Lamm DL, Blumenstein BA, Crissmann J et al. Maintenance bacillus Calmette-Guerin immunithe­rapy for recurrent TaT1 and carcinoma in situ transitional cell carcinoma of the bladder. A randomised sputhwest oncology group study. J Urol 2000; 163(4): 1124–1129.

26. Kaasinen E, Wijkstrom H, Malmstrom P et al. Alter­nating mitomycin C a BCG instilations versus BCG alone in tretament of carcinoma in situ of urinary bladder. A nordic stury. Eur Urol 2003; 43(6): 637–645.

27. O´Donnell MA. Treatment of Bacillus Calmette-Guerin Failures in patient with high-risk non-muscle Invasive Bladder Cancer. Genitourinary Cancers Symphosium Proceedings Book 2008: 55–56.

28. Alcaraz A. Bladder Cancer: Highlights from 2006. Eur Urol 2007; Supl 6(12): 737–744.

29. Berger A, Steiner H, Stenzl A et al. Photodynamic therapy with intravesicalinstilation of 5-aminolevulinic acid for patiens with recurent superfitial bladder cancer: a single centre study. Urology 2003; 61(2): 338–341.

Labels
Paediatric urologist Urology
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#